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Abstract Research on commensal microbiota and its contri-
bution to health and disease is a new and very dynamically
developing field of biology and medicine. Recent experimen-
tal and clinical investigations underscore the importance of
gut microbiota in the pathogenesis and course of stroke.
Importantly, microbiota may influence the outcome of cere-
bral ischemia by modulating central nervous system antigen-
specific immune responses. In this reviewwe summarize stud-
ies linking gut microbiota with physiological function and
disorders of the central nervous system. Based on these in-
sights we speculate about targeting the gut microbiome in
order to treat stroke.
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Introduction
The way we perceive microorganisms and their role in
health and disease has changed substantially over the last
few decades. It has long been recognized that human–mi-
crobial synergy in the gut promotes digestion and contrib-
utes to infections when the host–bacterial interaction is
disturbed. Recent discoveries, however, have enabled a
deeper understanding of the sophisticated interconnection
between commensal microbial populations and the host,
demonstrating that microbial communities not only refine
host metabolism, but also modulate immunity and even
contribute to organ development
The first systematic investigations of intestinal bacteria
were carried out in the nineteenth century [1]. When investi-
gating stool samples from healthy individuals Friedrich
Escherich cultured and characterized the Bacterium coli
commune, today known as Escherichia coli and Bthe work
horse of molecular biology^ [2]. Over the following decades
more commensal microorganisms were isolated and charac-
terized. But it is only the more recent implementation of ad-
vanced high-throughput genetic profiling that has given us
detailed insight into the cosmos of intestinal microorganisms.
Importantly, gut bacteria create a broad-ranging, dynamic mi-
crobial community that contributes substantially to processes
in the host organism and reacts to changes in host physiology.
Joshua Lederberg suggested the term Bmicrobiota^ to describe
this complex microbial population and defined it as Bthe eco-
logical community of commensal, symbiotic and pathogenic
microorganisms that literally share our body space^ [3]. The
microbiome is the collective genome of these symbiotic mi-
croorganisms and has a cumulative number of genes larger
than that in the human genome [4]. Commensal microorgan-
isms contribute substantially to host metabolism, providing
vitamins, extracting nutritional components, and metabolizing
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xenobiotics. They fortify the intestinal barrier and provide
colonization resistance through passive and active competi-
tion with potential pathogens [5]. In recent years, important
and previously unanticipated functions of commensal micro-
biota have been described. The gut microbiota has been
shown to contribute to the development of the immune sys-
tem, and, remarkably, also to the development of the central
nervous system (CNS) [6].
Thus, it is not at all a surprising suggestion that gut micro-
biota might play an important role under pathobiological con-
ditions and in physiological processes. Researchers have iden-
tified alterations in the composition of gut microbiota in sev-
eral diseases, such as inflammatory bowel disease [7], diabe-
tes [8], cancer [9], and disorders of the nervous system, for
example pain syndromes [10], Parkinson’s disease (PD) [11],
spinal cord injury [12], autism [13], and stroke [14–16].
Interestingly, aging is not only a risk factor of stroke, but also
affects the gut microbiome [17].While gut microbiota of older
individuals seems to be relatively stable over time, its compo-
sition differs substantially from that of younger people and is
very heterogeneous [18]. Compelling evidence comes from
experimental and clinical studies, and the number of investi-
gations into the role of commensal microbiota in neurological
disorders is growing constantly, putting the microbiome to the
spotlight in neuroscience. However, the variety and diversity
of the diseases, in which the involvement of microbiota has
been postulated is tremendous, and only detailed investiga-
tions in the coming years will show where the suggested con-
tribution of commensals is legitimate.
Despite all the uncertainties about the role of gut
microbiome, commensal microbiota is regarded as a promis-
ing therapeutic target and several research groups, start-ups,
and large companies have already commenced work on ther-
apies based on the gut microbiome [19, 20]. However, the
links between changes in composition of microbiota—which
are often the first observation reported in a particular condi-
tion—and the course of disease, have to be confirmed as caus-
ing or contributing to this condition. This would be the pre-
requisite for developing microbiome-targeted therapies. In
this review we want to discuss evidence for the involvement
of gut microbiome in the pathophysiology of CNS disorders
and speculate about therapeutic opportunities for manipula-
tions of gut microbiota in CNS disease, with a focus on stroke.
Microbiota and the CNS: Evidence for a Link
Impact of Gut Microbiota on the BHealth^ of the CNS:
Experimental Studies
Most insights into the role of microbiota in CNS development
and disease originate from studies in germ-free (GF) animals.
GF animals have no contact with any microorganisms at any
time in their life and are raised in sterile isolators. Establishing
the GF animals has proven that life without microbiota is pos-
sible [21]; GF organisms, however, have to be provided with
exogenous vitamins, otherwise they suffer from severe compli-
cations such as vitamin K deficiency, which leads to improper
coagulation [21]. Studies in GF mice have revealed that the GF
state leads to alterations in the nervous system (Table 1, for a
detailed review see [21]). The enteric nervous system in the
absence of microorganisms is not fully developed, and GFmice
have an altered intestinal motility [22]. The blood–brain barrier
in GF mice is more permeable [23], and microglia from GF
mice differ in morphology and function from that of conven-
tionally colonized animals [24]. Myelin component genes in
prefrontal cortex of GF animals are upregulated, an observation
that correlates with an increased thickness of the myelin sheath
in axons of GFmice [25]. Remarkably, GF status influences the
behavioral phenotype. Compared with specific pathogen-free
(SPF) animals, GF animals have increased motor activity and
decreased anxiety accompanied by differentially expressed
genes involved in synaptic circuitry [26]. Early colonization
of GF animals with conventional microbiota reverses this phe-
notype [26]. GF mice display an exaggerated stress response
due to hyper-responsiveness of the hypothalamus–pituitary–ad-
renal axis [27], and have impaired memory function [28].
Behavioral phenotypes characteristic for particular strains of
rodents (e.g., calm, tranquil nature of BALBc mice) can be
transmitted upon transfer of microbiota in experiments
using GF and conventionally colonized animals [29].
Neurobehavioral changes attributed to obesity, such as depres-
sion and dementia, were transferred with gut microbiome in an
experimental mouse model [30]. Several studies identified neu-
rochemical changes in the CNS of GF animals. For example,
compared with SPF mice, GF mice have an altered hippocam-
pal expression of brain-derived neurotrophic factor (BDNF),
but results regarding BDNF levels in GF animals are contradic-
tory [21, 26, 31]. BDNF is an important neurotrophic factor
impacting growth and survival of neurons and affecting synap-
tic transmission [32]. Additionally, male GFmice have elevated
levels of hippocampal serotonin and increased levels of plasma
tryptophan (serotonin precursor) [33]. Remarkably, microbiota
was shown to regulate serotonin synthesis in the periphery [34],
and GF animals have lower serotonin levels in plasma [35].
Communication pathways between the CNS and microbi-
ota involve immunological, endocrine, metabolic, and neural
pathways [36–38]. A direct neural connection between the gut
and the brain is provided by the vagus nerve. Intraduodenal
injection of Lactobacillus johnsonii caused increased gastral
vagal nerve signaling and reduced renal sympathetic nerve
activity in rats [39]. Long-term treatment with the probiotic
bacterium Lactobacillus rhamnosus in conventionally colo-
nized mice induced alterations in γ-aminobutryic acid
mRNA expression in specific brain regions and reduced anx-
iety and depression-related behavior, which was mediated by
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the vagus nerve [40]. Anxiolytic effects have been ascribed to
Bifidobacterium longum and were apparently mediated by the
vagus nerve in a mouse model of chemically induced colitis
[41]. The importance of other communication pathways has
been suggested, as, in a mouse model, antibiotic-induced
changes in behavior were independent of vagotomy or sym-
pathectomy [29]. Disturbances in either of the brain–gut mi-
crobiota axis pathwaysmight contribute to the development or
modulate the course of CNS disorders.
CNS Disorders and Microbiota: Experimental Studies
Links between microbiota and CNS diseases have been main-
ly investigated in rodent models of CNS disorders (Table 2)
[21, 37, 42–44], taking the advantage of GF animals. One of
the first reports on the role of gut microorganisms for the
development of CNS disease originated from the field of stud-
ies in an experimental autoimmune encephalomyelitis (EAE)
mouse model of multiple sclerosis (MS). Inflammatory T cell-
induced destruction of the myelin sheath is a key mechanism
in MS pathobiology. Notably, GF mice develop an attenuated
form of EAE or even no disease, compared with convention-
ally colonized mice [45, 46]. This has been attributed to
changes in the balance between proinflammatory T helper
17 and anti-inflammatory T regulatory (Tregs) lymphocytes,
which is shifted towards protective Tregs in GF animals.
Additionally, it has been shown that dendritic cells from GF
mice have a reduced ability to elicit proinflammatory re-
sponses [46]. In conventionally colonized hosts, gut microbi-
ota has also been identified as important disease modifier in
the EAE model. 2D2 myelin oligodendrocyte glycoprotein-
specific T cell transgenic mice are prone to develop EAE after
immunization [47]. Interestingly, susceptibility for EAE in
tumor necrosis factor receptor 2 knockout mice crossed with
2D2 mice is gender specific and associated with distinct mi-
crobiota patterns. Females are more prone to EAE, whereas
males, having different microbiome composition, are EAE
resistant. Additionally, antibiotic treatment ameliorates dis-
ease, suggesting a crucial role of microbiota in the develop-
ment of EAE [48]. Furthermore, EAE has been linked to the
dysfunction in the intestinal barrier [49]. In a very recent
report, a connection between dietary tryptophan, metabolized
by microbiota to aryl hydrocarbon receptor ligands and sever-
ity of EAE was established. Tryptophan reduced CNS inflam-
mation over modulation of astrocyte activity, which was me-
diated by aryl hydrocarbon receptor [50].
Interestingly, the therapeutic potential of the microbiota does
not appear to depend on the whole microbiota or on specific
subpopulations, but rather on several or even single bacterial
molecule. For example, the capsular polysaccharide from
Bacteroides fragilis protects mice from the development of in-
duced EAE, correlatingwith a shifted balance in the CD4+ cells
populations towards interleukin (IL)-10-producing CD4+
FoxP3 Treg cells [51]. Moreover, polysaccharide from
B. fragilis influences the maturation of the immune answer
and regulates the balance between Th1 and Th2 responses [52].
Beneficial effects of B. fragilis have also been investigated
in the murine maternal immune activation (MIA) model. MIA
shares common features with autism spectrum disorder in
humans. In this model, pregnant mice are injected with a syn-
thetic poly (I:C) double-stranded RNA mimicking viral infec-
tion. The offspring of poly I:C-injected mice display stereo-
typic behavior and deficits in social interaction and commu-
nication. They have altered, dysbiotic, composition of micro-
biota, accompanied by increased intestinal permeability and
distinct intestinal cytokine profiles. Treatment of MIA mice
with B. fragilis helps to rebalance the composition of micro-
biota, improves integrity of the epithelial barrier, and reverses
behavioral abnormalities [53].
In the field of studies on neuropsychiatric diseases, exper-
imental data suggest involvement of the microbiota in the
pathogenesis of eating disorders [54]. Furthermore, altered
microbiota composition has been reported in the mouse model
of depression [55]. In rodent models, early-life stress alters gut
microbiota composition [56, 57], and both stress-induced
pathophysiological changes in the host and gut microbiota
are necessary for the induction of anxiety-like behavior [57].
Evidence from experimental models suggests involvement of
gut microbiota in visceral pain syndromes [37].
Microbiota might also contribute to the development of
neurodegenerative CNS disorders, which has been demon-
strated in a mouse model of Alzheimer’s disease [58, 59].
Table 1 Differences in central
nervous system functions
between germ-free (GF) and con-
ventionally colonized mice
• ↑ BBB permeability [23]
• Distinct microglia morphology and function (immature microglia phenotype) [24]
• Hypermyelination of PFC axons [25]
• Behavioral changes, e.g., ↑ motor activity and ↓ anxiety [26], for review see [21]
• ↓ Memory functions [28]
• Neurochemical changes, e.g., altered BDNF levels [26, 31], ↑ levels of hippocampal serotonin in male GF
mice [33], for review see [21]
• Hyper-reactive HPA [27]
↑ = increased; ↓ = decreased; BBB = blood–brain barrier; PFC = prefrontal cortex; BDNF = brain-derived
neurotrophic factor; HPA = hypothalamic–pituitary–adrenal axis
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• Only mild form of EAE or no disease after EAE induction
in GF mice, linked with shifts in the Th17/Treg balance
and ↓ DC functions [45, 46]
• ↑ Relative abundance of species Bacteroides acidifaciens,
Bacteroides ovatus, Akkermansia muciniphila, ↑ relative
abundance of Oscillospira, Anaeroplasma and Sutterella
in male TNFR2-ko 2D2 transgenic mice resistant to EAE
compared with disease-susceptible females [48]
• PSA from B. fragilis ameliorates EAE symptoms when
given as therapy or prevention [51]
• ↑ Abundance of genera (Pseudomonas, Mycoplana,
Haemophilus, Blautia, Dorea) in patients with MS
compared with healthy controls ↑ Abundance of
Parabacteroides, Adlercreutzia, and Prevotella in
controls [73]
• ↑ Relative abundance of microorganisms from genera
pf Methanobrevibacter and Akkermansia, ↓ relative
abundance of Butyricimonas correlating with changes
in genes regulating immune response, ↓ abundance
of Collinsella, Slackia, and Prevotella, ↑ breath
methane concentrations in untreated patients with
MS compared with healthy controls; treatment linked
with alterations in the microbiome composition [74]
Eating disorders • Possible role of autoantibodies triggered by bacterial proteins
in the pathogenesis [54]
• Microbiome of anorexia nervosa patients vs healthy
controls: ↓ α-diversity, ↑ Bacilli class, unspecified
genus in Coriobacteriales family ↓ Clostridia class,
order Clostridiales, genera Anaerostipes and
Faecalibacterium; changes in microbiota with weight
restoration [136]
Depression • Different microbiota composition in mice after bilateral
olfactory bulbectomy (experimental model of depression)
as compared with sham-operated mice [55]
• Microbiota essential for the characteristic behavioral
phenotype after maternal separation in the mouse model
of depression [57]
• ↑ α-diversity and alterations in several bacterial
groups of gut microbiota in patients with active
major depressive disorder compared with healthy
controls, e.g., ↑ relative abundance of genera Alistipes,
Blautia, Clostridium XIX, Lachnospiracea incertae
sedis, Megamonas, Parabacteroides, Parasutterella,
Phascolarctobacterium, Oscillibacter, and Roseburia
in patients; ↑ abundance of genera Bacteroides, Dialister,
Faecalibacterium, Prevotella, and Ruminococcus
in healthy controls [111]
AD • ↓ Amyloid β pathology in GFAD mice [58]
• Antibiotic-induced dysbiosis linked with ↓ amyloid
pathology and ↓ gliosis in AD mouse model [59]
Stroke • Different microbiota composition in stroke mice compared
with sham-operated and naïve animals, ↑ relative abundance
of Peptococcaeae, and ↓ relative abundance of Prevotellaceae
correlating with lesion severity [15]
• ↓ α-diversity with several genera altered, ↓ intestinal
motility after stroke; proinflammatory immune cells
infiltrating the brain originate from the intestine; fecal
transplant with balanced microbiota has neuroprotective
effects [16]
• ↓ Lesion volume via downregulation of IL-17 γδT cells
in mice with dysbiotic microbiota [64]
• ↑ Mortality after stroke after extensive depletion of microbiota
by antibiotic pretreatment [67]
• Worse MCAo long-term outcome after microbiota
transplantation from an aged host [60]
• ↓ Neuronal injury and ↑ cognitive performance after
Clostridium butyricum treatment in bilateral common
carotid occlusion in diabetic mice (ischemia/reperfusion-
induced brain injury) [70]
• Dysbiotic microbiome in patients with stroke and
TIA: ↑ genera Enterobacter, Megasphaera, Oscillibacter,
and Desulfovibrio; ↓ genera Bacteroides, Prevotella,
and Faecalibacterium correlating with disease severity.
↓ TMAO in stroke/TIA group compared with patients
with asymptomatic atherosclerosis [14]
• ↓ Proportion of Roseburia, Bacteroides, and
Faecalibacterium prausnitzii in acute stroke compared
with healthy controls and patients with irritable
bowel syndrome, ↑proportion of Enterobacteriaceae,
Bifidobacteriaceae, and Clostridium difficile compared
with healthy controls; specific temporal changes of
microbial make-up after stroke with restoration after
a few weeks [75]
• Different microbiota composition in patients with
symptomatic atherosclerosis (minor brain infarction
= no severe functional deficits, TIA, occlusion of
the retinal artery) compared with healthy controls:
↑ Collinsella in atherosclerosis patients, whereas
↑ Roseburia, Eubacterium, and 3 species of Bacteroides
in controls [81]
• No differences in the composition of gut microbiome
between symptomatic atherosclerosis patients (minor
ischemic stroke, TIA, amaurosis fugax) and controls;
several bacterial groups originating possibly from
the gut microbiota detected in the atherosclerotic
plaques; correlation between microbiome composition
and lipid blood profile [78]
TBI • Correlation of TBI severity with changes in Bacteroidetes,
Bacteroidetes family, Porphyromonadaceae, Firmicutes,
and Proteobacteria [15]
SCI • Differences in gut microbiota composition in patients
with SCI compared with healthy controls: ↓ total
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Stroke and Microbiota: Experimental Studies
To date, only a few experimental studies focusing on the role
of gut microbiota in cerebral ischemia have been published.
Microbiota transferred from an aged host might contribute to
deterioration of functional long-term outcome in a mouse
model of focal cerebral ischemia [middle cerebral artery oc-
clusion (MCAo)] [60]. However, the exact mechanisms in-
volved in this process are not known [60]. In a rat MCAo
model, bacteria translocated from the gut to extraintestinal
organs after stroke, which might trigger systemic inflammato-
ry response or even cause poststroke infections [61].
Additionally, stress before stroke might boost bacterial trans-
location from the intestine into the bloodstream [62]. A recent
study demonstrated alterations in microbiota profile after se-
vere cerebral ischemia and linked poststroke dysbiosis
with induction of proinflammatory immune response.
Transplantation of balancedmicrobiota after cerebral ischemia
improved stroke outcome [16].
In another report antibiotic-induced gut dysbiosis with sig-
nificantly decreased α-diversity of gut microbiota (diversity
within particular habitat [63]) improved outcome and limited
the size of ischemic cerebral lesion as measured histologically
3 days afterMCAo. These effects were attributed to a decrease
in IL-17 producing γδ T cells and an increase in Treg cells in
the small intestine, and consequently limited infiltration of
harmful IL-17+ γδ T cells to the meninges [64].
Interestingly, similar mechanisms were suggested to ex-
plain the effects of high-fat diet on the pathogenesis of type
2 diabetes and obesity. A high-fat diet induced dysbiotic
changes in the gut microbiota, impaired function of antigen
presenting cells, and decreased number of IL-17 producers,
RORγt CD4+ T cells, in the intestine. These alterations pre-
ceded the onset of metabolic disease [65]. Obesity and diabe-
tes are, however, well-established risk factors for stroke [66].
Our group investigated the outcome of experimental stroke
in C57BL/6 mice after extensive microbiota depletion with
broad-spectrum antibiotic pretreatment [67].We observed sig-
nificantly increased mortality in microbiota-depleted animals
when the antibiotics were stopped before induction of cerebral
ischemia. Surprisingly, mortality was linked to acute severe
colitis. This phenotype was rescued upon colonization with
SPF microbiota or continuous antibiotic treatment. These ob-
servations underline the importance of the complex microbial
community after cerebral ischemia, when the host immune
system is severely compromised by stroke-induced
immunodepression [68], which affects immune barriers even
in the intestine [69]. We did not observe any effects of micro-
biota depletion on infarct volume in the brain 1 day after
MCAo [67].
Furthermore, model-specific changes in the microbiota af-
ter murine MCAo and mild traumatic brain injury were de-
scribed very recently. In MCAo animals alterations in
Peptococcaceae and Prevotellaceace correlated with infarct
severity. Additionally, inducing focal cerebral ischemia in
mice increased noradrenaline release in the gastrointestinal
tract (cecum), and reduced the number of mucoprotein-
producing cells and goblet cells. Increased noradrenaline
levels and changes in goblet cell function may directly affect
the gut microbial community after stroke [15].
A study in diabetic mice identified beneficial effects of




counts of bacteria from genera Pseudobutyrivibrio,
Dialister, andMegamonas in patients with UMN
bowel syndrome; ↓ total counts of microorganisms
from genera Roseburia, Pseudobutyrivibrio, and
Megamonas in patients with LMN bowel syndrome;
UMN vs LMN ↓ Marvinbryantia [12]
PD • ↓ Abundance of Prevotellaceae in patients with
PD compared with controls; specific bacterial
groups correlating with motor phenotype [11]
GBS • Involvement of Campylobacter jejuni in the
pathogenesis postulated [43]
ASD • Altered microbiota composition in the mouse model of
ASD, most important changes in classes Clostridia
and Bacteroidia [53]
• Several studies reporting microbiota changes in
children with ASD without consistent results,
reviewed in [137]
EAE = experimental autoimmune encephalomyelitis; MS = multiple sclerosis; GF = germ-free; Th = T helper; Treg = T regulatory; DC = dendritic cell;
TNFR2-ko = tumor necrosis factor receptor 2 knockout; PSA = polysaccharide; AD = Alzheimer’s disease; IL = interleukin; MCAo = middle cerebral
artery occlusion; TIA = transient ischemic attack; TMAO = trimethylamine N-oxide; TBI = traumatic brain injury; SCI = spinal cord injury; UMN =
upper motor neuron; LMN = lower motor neuron; PD = Parkinson’s disease; GBS = Guillain–Barré syndrome; ASD = autism spectrum disorder
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reperfusion-induced brain injury after bilateral common carot-
id artery occlusion. Treatment with C. butyricum decreased
neuronal injury and improved the cognitive functions [70]
Clinical Data
Clinical data on the brain–gut microbiota connection are still
scarce (Table 2). Hitherto, clinical microbiota research focused
on gastrointestinal, nutritional, or endocrine disorders such as
inflammatory bowel disease, obesity, or diabetes type 2.
First clinical reports on the role of gut microbiota indisorders
of the nervous system investigated alterations in the composition
of the gut microbiome with neurological disease but did not
provide a causative link. It was consequently conjectured that
gut microbiota plays a role in such different conditions as PD,
visceral pain, Guillain–Barré syndrome, stroke, and psychiatric
diseases [42, 43, 71]. Changes in the composition of gut micro-
biota have already been reported in PD. Patients with PD had
decreased abundance of Prevotellaceae in their microbiota com-
pared with control subjects. Increased abundance of
Enterobacteriaceaewas correlated with amore severemotor phe-
notype [11]. It is further hypothesized that gut microbiota may
also play a role in nonmotor symptoms of PD such as neuropsy-
chiatric conditions, sleep disturbances, and pain syndromes [72].
Spinal cord injury is another CNS disorder where the com-
position of microbiota has recently been investigated. Patients
with spinal cord injury have fewer butyrate-producing bacteria
in the gut; the consequences of this has not yet been clarified
[12]. Moreover, alterations in gut microbiota profiles were
observed in patients with MS [73, 74]. Interestingly, immuno-
modulatory treatment inMS had also effects on themicrobiota
composition [74].
Changes in the composition of microbiota in the course of
stroke were already reported [75], but more importantly,
microbiomemight contribute to the pathogenesis of the disease,
influencing formation of atherosclerotic plaque, as suggested
by experimental, as well as clinical data [76–78]. Microbiota
is involved in the metabolism of phosphatidylcholine.
Levels of its metabolites choline, betaine, and, in parti-
cular, trimethylamine N-oxide (TMAO; host product of
trimethylamine oxidation), have been identified as predictors
of cardiovascular disease risk [76, 77, 79, 80]. TMAO is also
produced during the metabolism of L-carnitine, which is found
in red meat [80]. All of these metabolites increase cholesterol
accumulation in macrophages and promote foam cell formation
[77]. Conversely, symptomatic atherosclerosis was linked to
changes in the composition of gut microbiome [81].
A recent clinical study compared microbiome composition
in patients diagnosed with asymptomatic atherosclerosis,
stroke, and transient ischemic attack. The trial data also in-
cluded patient TMAO plasma levels. Surprisingly, the asymp-
tomatic atherosclerosis group with and without carotid
plaques had similar levels of TMAO and comparable gut
microbiota composition. In contrast, patients with stroke and
transient ischemic attack differed substantially from the
asymptomatic subjects regarding microbiome composition,
but their TMAO levels were lower than those of the asymp-
tomatic group [14].
In another study, serum levels of carnitine and its metabolite
γ-butyrobetaine—rather than TMAOand trimethyllysine—were
elevated in patients with carotid atherosclerosis. Serum levels of
gamma-butyrobetaine and trimethyllysine were also associated
with cardiovascular death [82]. Conflicting evidence on gut mi-
crobiota metabolites and atherosclerosis was also submitted by
experimental studies. Atherosclerotic plaque formation was in-
creased in apolipoprotein E knockout transgenic mice (ApoE–/–;
mouse model of atherosclerosis [83]) when the mice were sup-
plemented with L-carnitine [80]. ApoE–/– animals, however, lack
an important enzyme cholesteryl ester transfer protein, which
transfers cholesterol ester between lipoproteins of high and low
density. Interestingly ApoE–/– transgenic mice overexpressing
human cholesteryl ester transfer protein supplemented with L-
carnitine had decreased aortic atherosclerotic plaque formation
and high TMAO levels [84]. Moreover, in contrast to conven-
tionally colonized ApoE–/– mice, the same transgenic animals
housed under GF conditions developed severe atherosclerosis
when fed a low cholesterol diet [85].
These data suggest that metabolites of the microbiome
might also provide a certain level of protection from the
development of disease. It should be noted that gut mi-
crobiota studies in the clinical settings are more challeng-
ing than experimental studies in animals. Study popula-
tions in humans are usually more heterogeneous, as they
are influenced by multiple factors independent of the dis-
order under investigation. These confounders might affect
the composition of the intestinal microbial community as
well [71]. Furthermore, as illustrated by the example of
studies in atherosclerosis, microbiota may confer dualistic
effects on the host—protective and harmful—in the path-
ogenesis and course of the disease [86] .
Open Issues and Future Avenues of Research
Gut Microbiota as Therapeutic Target in Stroke
Gut microbiota could be a potential therapeutic target for dis-
eases that constitute risk factors for stroke and/or for compli-
cations after cerebral ischemia (Fig. 1). Experimental and clin-
ical evidence suggests that microbiota in combination with a
high-fat diet contributes to the development of type 2 diabetes
[87], obesity [65, 87–91], and hypertension [92, 93]. Elevated
TMAO plasma levels, linked with adverse cardiovascular
events in humans, were normalized by antibiotic treatment
[79]. However, prolonged antibiosis for atherosclerosis pre-
vention is potentially harmful as it poses an increased risk of
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antibiotic resistance and detrimental infections such as
Clostridium difficile colitis. In a more sophisticated approach,
TMAO production has been successfully inhibited by 3,3-di-
methyl-1-butanol, a structural analog of choline and an antag-
onist for the microbial trimethylamine lyase [94].
Further, microbiome-based therapy appears to be a prom-
ising approach for the treatment of poststroke complications.
Complications after cerebral ischemia comprise, among
others, bacterial infections, cognitive impairment, and de-
pression [95, 96]. In particular, stroke-associated pneumonia
is considered to contribute to detrimental neurological out-
come. We would speculate that these conditions can be
targeted via the gut microbiome. Although experimental
findings are equivocal, gut microbiota might be the source
of systemic infections in patients with stroke, particularly
when host immunity and immunological barriers are com-
promised by poststroke immunodepression [97]. In a mouse
model gut microbiota has been demonstrated to support the
host immune defense against pneumococcal pneumonia
[98]. After microbiota depletion with antibiotic treatment,
C57BL/6 mice infected with Streptococcus pneumoniae
showed higher mortality, more severe organ damage, in-
creased spread of the pathogen, elevated inflammatory
markers, and limited alveolar macrophages functions than
did untreated mice. Transfer of fecal microbiota from un-
treated animals reduced bacterial counts in the lungs and
normalized inflammatory markers. [98]. Whether the gut
microbiota or rather the microbiota of the respiratory tract
is responsible for these effects remains a matter of debate.
Both microbial communities are affected by the antibiotic
treatment used in this study to deplete the microbiota, as
well as by fecal transplantation over oral gavage, implement-
ed to restore microbial community [99].
In current practice patients with stroke are often treated
with antibiotics in the acute course of the disease due to
poststroke infections. Certainly, antibiotic treatment will target
not only pathogens in lung and urinary tract, but also the
commensal bacterial populations in other organs such as the
Fig. 1 Modifiable stroke risk factors and poststroke complications with
hypothesized involvement of the gut microbiota. Gut microbiota might
contribute to the pathogenesis of cerebrovascular disorders and serve as a
therapeutic target for modulating stroke-related risk factors,
neuroinflammatary responses, and complications after stroke. The inter-
play between the gut microbiome and the host involves the host immune
system, hypothalamus–pituitary–adrenal glands axis (HPA), autonomic
nervous system, enteric nervous system (ENS), and microbial molecules
and metabolites. Th = T helper; Treg = T regulatory; FMT = fecal micro-
bial transplantation; FIAF = fasting-induced adipose factor; AMPK = 5'
adenosine monophosphate-activated protein kinase; LPS =
lipopolysacharide; TMA = trimethylamine; SCFA = short-chain fatty
acids
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gut. Antibiotics induce rapid and long-lasting changes in the
microbiome [100]. Treatment with clindamycin over 7 days
triggered shifts in the microbiota, detected even 2 years after
the termination of the antibiotic therapy [101]. Patients with
severe strokes are usually treated for 5 to 10 days and often
with combinations of broad-spectrum antimicrobial agents
[102]. In experimental stroke, profound depletion of microbi-
ota by extensive broad-spectrum antibiotic pretreatment to
eliminate cultivatable bacterial microorganisms causes detri-
mental outcome due to acute and severe colitis [67].
Investigations in an animal model [103], as well as in a clin-
ical study [104], suggest that stroke triggers ametabolic switch to
a catabolic profile, causing sarcopenia and substantial weight
loss. Although the underlyingmechanisms are not fully elucidat-
ed, involvement of commensal bacteria is likely. It has been
suggested that shifts in microbiota are associated with weight
changes [105]. Altered composition of gut microbiota has been
observed in a mouse model of acute leukemia accompanied by
cachexia [106]. Restoration of specific microbial species led to
reduction of the inflammatory cytokines andmarkers involved in
the protein breakdown in skeletal muscle [106].
Stroke survivors often suffer from neuropsychiatric com-
plications, mainly poststroke depression [95]. It has been
shown that a multitude of mechanisms, including systemic
inflammatory processes, are involved in the manifestation of
poststroke depression [107]. However, it is also reasonable to
assume a role for gut microbiota, as experimental and clinical
studies suggest a causative role of microbiota in mood disor-
ders [108–111].
The abovementioned relations are largely speculative but
ultimately testable. They provide examples for how gut
microbiome might serve as target to treat or even prevent
conditions that pose risk factors for stroke or poststroke
complications.
Therapeutic Manipulation of the Microbiome?
Principally, there are two strategies for manipulating microbi-
ota: 1) target a defined microorganism by direct elimination,
modification, or triggering of the immune response via vacci-
nation with a specific epitope; and 2) manipulate whole com-
munities either individually or by combinations of antibiotics,
probiotics, prebiotics, synbiotics, or fecal transplant [112].
Targeting specific microbiota is promising when a causal
link has been demonstrated between a particular microorgan-
ism and a disease. The approach of targeting whole commu-
nities appears to be a shot in the dark: the outcome of such a
therapy is not only unpredictable, but might also have more
severe adverse effects, in particular when the entire microbial
community is profoundly influenced. As already discussed,
antibiotic treatment might shift the gut microbiome incurring
detrimental outcome, in particular in immune compromised
patients with stroke. In contrast, several probiotics have been
shown to exert beneficial effects on the human immune sys-
tem [113], while difficulties can and do arise owing to the fact
that some bacterial strains are not even able to survive the
human upper gastrointestinal tract, and often do not colonize
the gut. The choice of which probiotic strain to use as a treat-
ment is therefore complicated. Commonly, probiotic supple-
mentation is considered to be well tolerated. However, treat-
ment with probiotics might have harmful consequences. For
example, the PROPATRIA (PRObiotics in PAncreatitits
TRIAl) trial had to be stopped prematurely owing to signifi-
cantly higher mortality in the group treated with probiotics
[114, 115]. Moreover, several immunocompromised patients
or newborns are reported to have suffered from sepsis due to
probiotic microorganisms [116–118]. These findings advise
caution, given that stroke induces an immune depression [68].
Ever since 1958, transfer of a whole microbiota community
from a healthy donor, so-called fecal microbiota transplanta-
tion (FMT), has been established in the treatment of patients
with severe C. difficile colitis. At that time the causative agent
had not even been identified [119]. The effectiveness of FMT
in pseudomembranous colitis was recently confirmed by a
clinical study comparing FMT with vancomycin treatment
[120]. However, the optimal way of delivering the
Btransplant^ to the gut has not yet been established. Studies
are being carried out to improve fecal bacteriotherapy in order
to recolonize the gut with microorganisms from healthy do-
nors [121]. Delivering fecal microbiota by pill allows stan-
dardization and might reduce risks associated with the more
invasive delivery [122]. However, standards for identifica-
tions of persons who qualify as healthy donors are also not
yet fully established. Since the field of microbial therapy is in
its infancy and little is known about side effects, transplanta-
tion of currently unknown pathogenic microorganisms by
FMT cannot be excluded. Some undesirable and hitherto un-
predictable effects of FMT have been already reported, for
example peripheral neuropathy [123]. Moreover, in the exper-
imental setting, transplantation of intestinal microbiota from
an atherosclerosis-prone to a disease-resistant mouse strain
was sufficient to transmit susceptibility to atherosclerosis
[124]. Thus, even before risk factors for diseases manifest,
gut microbiota might have pathogenic potential, making the
definition of healthy persons as donors for FMT inherently
difficult. Nonetheless, stool transplant has already been ap-
proved in USA by the Federal Drug Administration for
treating C. difficile enteritis that is nonresponsive to standard
therapies; however, the legal status of FMT is still being de-
bated [125]. Furthermore, novel therapeutic approaches, spe-
cifically targeting microbiome are developing rapidly, includ-
ing phage therapy, targeting quorum-sensing molecules, or
certain bacterial genes [100, 126].
High expectations for developing new microbiota-based
therapies are pinned on the microbial interplay with the im-
mune system and the metabolic capacity of the microbiome.
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Gut microbiota possesses metabolic capacities comparable
with those of a human liver [127]. Products of bacterial fer-
mentation, short-chain fatty acids, modulate immune re-
sponses [128], and might contribute to the pathogenesis of
hypertension [93]. Moreover, gut bacteria can directly metab-
olize drugs to influence their activity or indirectly modify host
responses to xenobiotics [129]. This has implications for the
bioavailability of drugs and their toxicity. For example, levo-
dopa, used in the treatment of PD, needs to be decarboxylated
to dopamine in the CNS. Intestinal bacteria are also capable of
decarboxylating the drug [130]. However, levodopa, but not
dopamine, is able to cross the blood–brain barrier, so decar-
boxylation outside the CNS would affect its brain availability
[131].
In an experimental mouse study, nonlethal inhibition of
bacterial β-glucuronidases, which reactivate the colon cancer
drug CPT-11 (Irinotecan), lead to alleviation of the drug's
toxicity [132]. These effects seem to depend on a specific
composition of gut bacteria. Gut microbiota (and, specifically,
Bacteroides species) has proved to be indispensable for effi-
cacy of certain anticancer drugs (Ipilimumab, anti-cytotoxic
T-lymphocyte-associated protein 4), which are unsuccessful in
GF or antibiotic-treated mice [133]. Bifidobacterium promot-
ed success of antitumor therapy with anti-programmed cell-
death-ligand 1 by boosting T-cell responses [134].
Taken together, composition of gut microbiota might influ-
ence treatment success of certain drugs through its microbial
metabolic functions or by modulating the immune response.
This field of research certainly needs to be followed up to
disentangle the therapeutic potential of the commensal micro-
organisms and help to predict individual responses to certain
therapies. It appears very likely that many commonly used
drugs, not investigated in the context of gut microbial compo-
sition, might exert their effects, at least in part, on microorgan-
isms of the gut.
One of the main obstacles in current microbiome-based
treatment research is the definition of measurable and clinical-
ly relevant microbiota-related endpoints for predicting the
success of the therapy [135]. There is no generally accepted
method or even gold standard for monitoring microbiota that
could be implemented in the clinical setting. More important-
ly, relevant endpoints for efficacy, comparable with clinical
trials investigating drugs for treatment, need to be used to
prove a causative link between a certain microbiota composi-
tion and a particular condition, and to provide a novel
microbiome-based treatment strategy [135].
In summary, gut microbiota research is a flourishing field
with novel and often surprising discoveries about the role of
commensal microorganisms in health and disease. Thanks to
the advances in sampling and sequencing techniques, the de-
tailed characterization and profiling of microbiome is now
feasible. Although the concept of gut microbiota–brain com-
munication seems to be established now, investigations are
still needed to characterize the mechanistic connections be-
tween changes in the gut microbiota and neurological dis-
eases. This would be the prerequisite for developing success-
ful microbiota-based therapies in CNS disorders, the effective-
ness and safety of which would need to be tested in experi-
mental studies and large clinical trials. Although most of this
research has been done outside neurosciences, we provided
examples, which we believe to be instructive for stroke
research.
Required Author Forms Disclosure forms provided by the authors are
available with the online version of this article.
Compliance with Ethical standards
Funding This work was supported by the German Research
Foundation (Exc 257) and the Federal Ministry of Education and
Research (01 EO 08 01). KW received PhD scholarship from the
International Max Planck Research School for Infectious Diseases and
Immunology (IMPRS-IDI) and the Sonnenfeld-Stiftung. We thank Ms.
Catherine Aubel for proofreading the manuscript.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Rettger, L.F., A Treatise on the Transformation of the Intestinal
Flora. London: Forgotten Books. (Original work published 1921).
(2013).
2. Shulman, S.T., Friedmann, H.C., and Sims, R.H., Theodor
Escherich: the first pediatric infectious diseases physician? Clin
Infect Dis, 2007. 45(8): p. 1025-9.
3. Grice, E.A. and Segre, J.A., The human microbiome: our second
genome. Annu Rev Genomics Hum Genet, 2012. 13: p. 151-70.
4. Xu, J. and Gordon, J.I., Honor thy symbionts. Proc Natl Acad Sci
U S A, 2003. 100(18): p. 10452-9.
5. O'Hara, A.M. and Shanahan, F., The gut flora as a forgotten organ.
EMBO Rep, 2006. 7(7): p. 688-93.
6. Borre, Y.E., O'Keeffe, G.W., Clarke, G., Stanton, C., Dinan, T.G.,
and Cryan, J.F., Microbiota and neurodevelopmental windows:
implications for brain disorders. Trends Mol Med, 2014. 20(9):
p. 509-18.
7. Butto, L.F. and Haller, D., Dysbiosis in intestinal inflammation:
Cause or consequence. Int J Med Microbiol, 2016.
8. Karlsson, F.H., Tremaroli, V., Nookaew, I., et al., Gut metagenome
in European women with normal, impaired and diabetic glucose
control. Nature, 2013. 498(7452): p. 99-103.
9. Bultman, S.J., Emerging roles of the microbiome in cancer.
Carcinogenesis, 2014. 35(2): p. 249-55.
10. Mayer, E.A., Knight, R., Mazmanian, S.K., Cryan, J.F., and
Tillisch, K., Gut microbes and the brain: paradigm shift in neuro-
science. J Neurosci, 2014. 34(46): p. 15490-6.
770 Winek et al.
11. Scheperjans, F., Aho, V., Pereira, P.A., et al., Gut microbiota are
related to Parkinson's disease and clinical phenotype. MovDisord,
2015. 30(3): p. 350-8.
12. Gungor, B., Adiguzel, E., Gursel, I., Yilmaz, B., and Gursel, M.,
Intestinal Microbiota in Patients with Spinal Cord Injury. PLoS
One, 2016. 11(1): p. e0145878.
13. De Angelis,M., Francavilla, R., Piccolo,M., DeGiacomo, A., and
Gobbetti, M., Autism spectrum disorders and intestinal microbio-
ta. Gut Microbes, 2015. 6(3): p. 207-13.
14. Yin, J., Liao, S.X., He, Y., et al., Dysbiosis of GutMicrobiotaWith
Reduced Trimethylamine-N-Oxide Level in Patients With Large-
Artery Atherosclerotic Stroke or Transient Ischemic Attack. J Am
Heart Assoc, 2015. 4(11).
15. Houlden, A., Goldrick,M., Brough, D., et al., Brain injury induces
specific changes in the caecal microbiota of mice via altered auto-
nomic activity and mucoprotein production. Brain Behav Immun,
2016.
16. Singh, V., Roth, S., Llovera, G., et al., Microbiota Dysbiosis
Controls the Neuroinflammatory Response after Stroke. J
Neurosci, 2016. 36(28): p. 7428-40.
17. O'Toole, P.W. and Claesson, M.J., Gut microbiota: Changes
throughout the lifespan from infancy to elderly. International
Dairy Journal, 2010. 20(4): p. 281-291.
18. Claesson, M.J., Cusack, S., O'Sullivan, O., et al., Composition,
variability, and temporal stability of the intestinal microbiota of the
elderly. Proc Natl Acad Sci U S A, 2011. 108 Suppl 1: p. 4586-91.
19. Reardon, S., Microbiome therapy gains market traction. Nature,
2014. 509(7500): p. 269-70.
20. Garber, K., Drugging the gut microbiome. Nat Biotechnol, 2015.
33(3): p. 228-31.
21. Luczynski, P., McVey Neufeld, K.A., Oriach, C.S., Clarke, G.,
Dinan, T.G., and Cryan, J.F., Growing up in a Bubble: Using
Germ-Free Animals to Assess the Influence of the Gut
Microbiota on Brain and Behavior. Int J Neuropsychopharmacol,
2016.
22. Collins, J., Borojevic, R., Verdu, E.F., Huizinga, J.D., and
Ratcliffe, E.M., Intestinal microbiota influence the early postnatal
development of the enteric nervous system. Neurogastroenterol
Motil, 2014. 26(1): p. 98-107.
23. Braniste, V., Al-Asmakh, M., Kowal, C., et al., The gut microbiota
influences blood-brain barrier permeability in mice. Sci Transl
Med, 2014. 6(263): p. 263ra158.
24. Erny, D., Hrabe de Angelis, A.L., Jaitin, D., et al., Host microbiota
constantly control maturation and function of microglia in the
CNS. Nat Neurosci, 2015. 18(7): p. 965-77.
25. Hoban, A.E., Stilling, R.M., Ryan, F.J., et al., Regulation of pre-
frontal cortex myelination by the microbiota. Transl Psychiatry,
2016. 6: p. e774.
26. Heijtz, R.D., Wang, S., Anuar, F., et al., Normal gut microbiota
modulates brain development and behavior. Proceedings of the
National Academy of Sciences of the United States of America,
2011. 108(7): p. 3047-52.
27. Sudo, N., Chida, Y., Aiba, Y., et al., Postnatal microbial coloniza-
tion programs the hypothalamic-pituitaryadrenal system for stress
response in mice. J Physiol, 2004. 558(Pt 1): p. 263-75.
28. Gareau, M.G., Wine, E., Rodrigues, D.M., et al., Bacterial infec-
tion causes stress-induced memory dysfunction in mice. Gut,
2010.
29. Bercik, P., Denou, E., Collins, J., et al., The Intestinal Microbiota
Affect Central Levels of Brain-Derived Neurotropic Factor and
Behavior in Mice. Gastroenterology, 2011.
30. Bruce-Keller, A.J., Salbaum, J.M., Luo, M., et al., Obese-type gut
microbiota induce neurobehavioral changes in the absence of obe-
sity. Biol Psychiatry, 2015. 77(7): p. 607-15.
31. Neufeld, K.M., Kang, N., Bienenstock, J., and Foster, J.A.,
Reduced anxiety-like behavior and central neurochemical change
in germ-free mice. Neurogastroenterol Motil, 2011. 23(3): p. 255-
64, e119.
32. Binder, D.K. and Scharfman, H.E., Brain-derived neurotrophic
factor. Growth Factors, 2004. 22(3): p. 123-31.
33. Clarke, G., Grenham, S., Scully, P., et al., The microbiome-gut-
brain axis during early life regulates the hippocampal serotonergic
system in a sex-dependent manner. Mol Psychiatry, 2012.
34. Yano, J.M., Yu, K., Donaldson, G.P., et al., Indigenous bacteria
from the gut microbiota regulate host serotonin biosynthesis. Cell,
2015. 161(2): p. 264-76.
35. Wikoff, W.R., Anfora, A.T., Liu, J., et al., Metabolomics analysis
reveals large effects of gut microflora on mammalian blood me-
tabolites. Proc Natl Acad Sci U S A, 2009. 106(10): p. 3698-703.
36. Collins, S.M., Surette, M., and Bercik, P., The interplay between
the intestinal microbiota and the brain. Nat Rev Microbiol, 2012.
10(11): p. 735-42.
37. Cryan, J.F. and Dinan, T.G., Mind-altering microorganisms: the
impact of the gut microbiota on brain and behaviour. Nat Rev
Neurosci, 2012. 13(10): p. 701-12.
38. Rhee, S.H., Pothoulakis, C., and Mayer, E.A., Principles and clin-
ical implications of the brain-gut-enteric microbiota axis. Nat Rev
Gastroenterol Hepatol, 2009. 6(5): p. 306-14.
39. Tanida, M., Yamano, T., Maeda, K., Okumura, N., Fukushima, Y.,
and Nagai, K., Effects of intraduodenal injection of Lactobacillus
johnsonii La1 on renal sympathetic nerve activity and blood pres-
sure in urethaneanesthetized rats. Neurosci Lett, 2005. 389(2): p.
109-14.
40. Bravo, J.A., Forsythe, P., Chew, M.V., et al., Ingestion of
Lactobacillus strain regulates emotional behavior and central
GABA receptor expression in a mouse via the vagus nerve. Proc
Natl Acad Sci U S A, 2011. 108(38): p. 16050-5.
41. Bercik, P., Park, A.J., Sinclair, D., et al., The anxiolytic effect of
Bifidobacterium longum NCC3001 involves vagal pathways for
gut-brain communication. Neurogastroenterol Motil, 2011.
23(12): p. 1132-9.
42. Ochoa-Reparaz, J., Mielcarz, D.W., Begum-Haque, S., and
Kasper, L.H., Gut, bugs, and brain: Role of commensal bacteria
in the control of central nervous system disease. Ann Neurol,
2011. 69(2): p. 240-7.
43. Wang, Y. and Kasper, L.H., The role of microbiome in central
nervous system disorders. Brain Behav Immun, 2014. 38: p. 1-12.
44. Mayer, E.A., Tillisch, K., and Gupta, A., Gut/brain axis and the
microbiota. J Clin Invest, 2015. 125(3): p. 926-38.
45. Berer, K., Mues, M., Koutrolos, M., et al., Commensal microbiota
and myelin autoantigen cooperate to trigger autoimmune demye-
lination. Nature, 2011. 479(7374): p. 538-41.
46. Lee, Y.K., Menezes, J.S., Umesaki, Y., and Mazmanian, S.K.,
Proinflammatory T-cell responses to gut microbiota promote ex-
perimental autoimmune encephalomyelitis. Proc Natl Acad Sci U
S A, 2011. 108 Suppl 1: p. 4615-22.
47. Bettelli, E., Pagany, M., Weiner, H.L., Linington, C., Sobel, R.A.,
and Kuchroo, V.K., Myelin oligodendrocyte glycoprotein-specific
T cell receptor transgenic mice develop spontaneous autoimmune
optic neuritis. J Exp Med, 2003. 197(9): p. 1073-81.
48. Miller, P.G., Bonn, M.B., Franklin, C.L., Ericsson, A.C., and
McKarns, S.C., TNFR2 Deficiency Acts in Concert with Gut
Microbiota To Precipitate Spontaneous Sex-Biased Central
Nervous System Demyelinating Autoimmune Disease. J
Immunol, 2015. 195(10): p. 4668-84.
49. Nouri, M., Bredberg, A., Westrom, B., and Lavasani, S., Intestinal
barrier dysfunction develops at the onset of experimental autoim-
mune encephalomyelitis, and can be induced by adoptive transfer
of autoreactive T cells. PLoS One, 2014. 9(9): p. e106335.
50. Rothhammer, V., Mascanfroni, I.D., Bunse, L., et al., Type I inter-
ferons and microbial metabolites of tryptophan modulate astrocyte
Therapeutic Manipulations of the Gut Microbiome in CNS Diseases 771
activity and central nervous system inflammation via the aryl hy-
drocarbon receptor. Nat Med, 2016.
51. Ochoa-Reparaz, J., Mielcarz, D.W., Wang, Y., et al., A polysac-
charide from the human commensal Bacteroides fragilis protects
against CNS demyelinating disease. Mucosal Immunology, 2010.
3(5): p. 487-495.
52. Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., and Kasper, D.L.,
An immunomodulatory molecule of symbiotic bacteria directs
maturation of the host immune system. Cell, 2005. 122(1): p.
107-18.
53. Hsiao, E.Y., McBride, S.W., Hsien, S., et al., Microbiota modulate
behavioral and physiological abnormalities associated with
neurodevelopmental disorders. Cell, 2013. 155(7): p. 1451-63.
54. Tennoune, N., Chan, P., Breton, J., et al., Bacterial ClpB heat-
shock protein, an antigen-mimetic of the anorexigenic peptide
alpha-MSH, at the origin of eating disorders. Transl Psychiatry,
2014. 4: p. e458.
55. Park, A.J., Collins, J., Blennerhassett, P.A., et al., Altered colonic
function and microbiota profile in a mouse model of chronic de-
pression. Neurogastroenterol Motil, 2013. 25(9): p. 733-e575.
56. O'Mahony, S.M., Marchesi, J.R., Scully, P., et al., Early life stress
alters behavior, immunity, and microbiota in rats: implications for
irritable bowel syndrome and psychiatric illnesses. Biol
Psychiatry, 2009. 65(3): p. 263-7.
57. De Palma, G., Blennerhassett, P., Lu, J., et al., Microbiota and host
determinants of behavioural phenotype in maternally separated
mice. Nat Commun, 2015. 6: p. 7735.
58. Harach, T.M., N.; Dutilleul, N.; Cheatham, V., et al., Reduction of
Alzheimer's disease beta-amyloid pathology in the absence of gut
microbiota. arXiv:1509.02273v2 [q-bio.MN].
59. Minter, M.R., Zhang, C., Leone, V., et al., Antibiotic-induced
perturbations in gut microbial diversity influences neuro-inflam-
mation and amyloidosis in a murine model of Alzheimer's disease.
Sci Rep, 2016. 6: p. 30028.
60. Jandzinski, M., Manipulation of the microbiome and its impact on
functional recovery following ischemic stroke. Honors Scholar
Theses. Paper 414, 2015: p. http://digitalcommons.uconn.
edu/srhonors_theses/414.
61. Tascilar, N., Irkorucu, O., Tascilar, O., et al., Bacterial transloca-
tion in experimental stroke: what happens to the gut barrier?
Bratisl Lek Listy, 2010. 111(4): p. 194-9.
62. Caso, J.R., Hurtado, O., Pereira, M.P., et al., Colonic bacterial
translocation as a possible factor in stressworsening experimental
stroke outcome. Am J Physiol Regul Integr Comp Physiol, 2009.
296(4): p. R979-85.
63. Whittaker, R.H., Evolution and Measurement of Species
Diversity. Taxon, 1972. 21(2/3 ): p. 213-251.
64. Benakis, C., Brea, D., Caballero, S., et al., Commensal microbiota
affects ischemic stroke outcome by regulating intestinal
gammadelta T cells. Nat Med, 2016. 22(5): p. 516-23.
65. Garidou, L., Pomie, C., Klopp, P., et al., The Gut Microbiota
Regulates Intestinal CD4 T Cells Expressing RORgammat and
Controls Metabolic Disease. Cell Metab, 2015. 22(1): p. 100-12.
66. Sacco, R.L., Benjamin, E.J., Broderick, J.P., et al., AmericanHeart
Association Prevention Conference. IV. Prevention and
Rehabilitation of Stroke. Risk factors. Stroke, 1997. 28(7): p.
1507-17.
67. Winek, K., Engel, O., Koduah, P., et al., Depletion of Cultivatable
Gut Microbiota by Broad-Spectrum Antibiotic Pretreatment
Worsens Outcome After Murine Stroke. Stroke, 2016. 47(5): p.
1354-63.
68. Meisel, C., Schwab, J.M., Prass, K., Meisel, A., and Dirnagl, U.,
Central nervous system injury-induced immune deficiency syn-
drome. Nat Rev Neurosci, 2005. 6(10): p. 775-86.
69. Schulte-Herbruggen, O., Quarcoo, D., Meisel, A., and Meisel, C.,
Differential affection of intestinal immune cell populations after
cerebral ischemia inmice. Neuroimmunomodulation, 2009. 16(3):
p. 213-8.
70. Sun, J.,Wang, F., Ling, Z., et al., Clostridium butyricum attenuates
cerebral ischemia/reperfusion injury in diabetic mice via modula-
tion of gut microbiota. Brain Res, 2016.
71. Winek, K., Meisel, A., and Dirnagl, U., Gut microbiota impact on
stroke outcome: Fad or fact? J Cereb Blood Flow Metab, 2016.
36(5): p. 891-8.
72. Felice, V.D., Quigley, E.M., Sullivan, A.M., O'Keeffe, G.W., and
O'Mahony, S.M., Microbiota-gut-brain signalling in Parkinson's
disease: Implications for non-motor symptoms. Parkinsonism
Relat Disord, 2016.
73. Chen, J., Chia, N., Kalari, K.R., et al., Multiple sclerosis patients
have a distinct gut microbiota compared to healthy controls. Sci
Rep, 2016. 6: p. 28484.
74. Jangi, S., Gandhi, R., Cox, L.M., et al., Alterations of the human
gut microbiome in multiple sclerosis. Nat Commun, 2016. 7: p.
12015.
75. Swidsinski, A.L.-B., V.; Krüger, M.; Kirsch, S., Central Nervous
System and the Colonic Bioreactor: Analysis of Colonic
Microbiota in Patients with Stroke Unravels Unknown
Mechanisms of the Host Defense after Brain Injury. Intest Res,
2012. 10(4): p. 332-342.
76. Zhu, W., Gregory, J.C., Org, E., et al., Gut Microbial Metabolite
TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.
Cell, 2016. 165(1): p. 111-24.
77. Wang, Z., Klipfell, E., Bennett, B.J., et al., Gut flora metabolism of
phosphatidylcholine promotes cardiovascular disease. Nature,
2011. 472(7341): p. 57-63.
78. Koren, O., Spor, A., Felin, J., et al., Human oral, gut, and plaque
microbiota in patients with atherosclerosis. Proc Natl Acad Sci U
S A, 2010. 108 Suppl 1: p. 4592-8.
79. Tang, W.H., Wang, Z., Levison, B.S., et al., Intestinal microbial
metabolism of phosphatidylcholine and cardiovascular risk. N
Engl J Med, 2013. 368(17): p. 1575-84.
80. Koeth, R.A., Wang, Z., Levison, B.S., et al., Intestinal microbiota
metabolism of L-carnitine, a nutrient in red meat, promotes ath-
erosclerosis. Nat Med, 2013. 19(5): p. 576-85.
81. Karlsson, F.H., Fak, F., Nookaew, I., et al., Symptomatic athero-
sclerosis is associated with an altered gut metagenome. Nat
Commun, 2012. 3: p. 1245.
82. Skagen, K., Troseid, M., Ueland, T., et al., The Carnitine-
butyrobetaine-trimethylamine-N-oxide pathway and its associa-
tion with cardiovascular mortality in patients with carotid athero-
sclerosis. Atherosclerosis, 2016. 247: p. 64-9.
83. Meir, K.S. and Leitersdorf, E., Atherosclerosis in the apolipopro-
tein-E-deficient mouse: a decade of progress. Arterioscler Thromb
Vasc Biol, 2004. 24(6): p. 1006-14.
84. Collins, H.L., Drazul-Schrader, D., Sulpizio, A.C., et al., L-
Carnitine intake and high trimethylamine Noxide plasma levels
correlate with low aortic lesions in ApoE(-/-) transgenic mice
expressing CETP. Atherosclerosis, 2016. 244: p. 29-37.
85. Stepankova, R., Tonar, Z., Bartova, J., et al., Absence of microbi-
ota (germ-free conditions) accelerates the atherosclerosis in ApoE-
deficient mice fed standard low cholesterol diet. J Atheroscler
Thromb, 2010. 17(8): p. 796-804.
86. Singh, V., Yeoh, B.S., and Vijay-Kumar, M., Gut microbiome as a
novel cardiovascular therapeutic target. Curr Opin Pharmacol,
2016. 27: p. 8-12.
87. Hartstra, A.V., Bouter, K.E., Backhed, F., and Nieuwdorp, M.,
Insights into the role of the microbiome in obesity and type 2
diabetes. Diabetes Care, 2015. 38(1): p. 159-65.
88. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., et al., A core gut
microbiome in obese and lean twins. Nature, 2009. 457(7228): p.
480-4.
772 Winek et al.
89. Backhed, F., Ding, H., Wang, T., et al., The gut microbiota as an
environmental factor that regulates fat storage. Proc Natl Acad Sci
U S A, 2004. 101(44): p. 15718-23.
90. Backhed, F., Manchester, J.K., Semenkovich, C.F., and Gordon,
J.I., Mechanisms underlying the resistance to diet-induced obesity
in germ-free mice. Proc Natl Acad Sci U S A, 2007. 104(3): p.
979-84.
91. Fu, J., Bonder, M.J., Cenit, M.C., et al., The Gut Microbiome
Contributes to a Substantial Proportion of the Variation in Blood
Lipids. Circ Res, 2015. 117(9): p. 817-24.
92. Durgan, D.J., Ganesh, B.P., Cope, J.L., et al., Role of the Gut
Microbiome in Obstructive Sleep Apnea- Induced Hypertension.
Hypertension, 2016. 67(2): p. 469-74.
93. Santisteban, M.M., Kim, S., Pepine, C.J., and Raizada, M.K.,
Brain-Gut-Bone Marrow Axis: Implications for Hypertension
and Related Therapeutics. Circ Res, 2016. 118(8): p. 1327-36.
94. Wang, Z., Roberts, A.B., Buffa, J.A., et al., Non-lethal Inhibition
of Gut Microbial Trimethylamine Production for the Treatment of
Atherosclerosis. Cell, 2015. 163(7): p. 1585-95.
95. Langhorne, P., Stott, D.J., Robertson, L., et al., Medical compli-
cations after stroke: a multicenter study. Stroke, 2000. 31(6): p.
1223-9.
96. Westendorp, W.F., Nederkoorn, P.J., Vermeij, J.D., Dijkgraaf,
M.G., and de Beek, D., Post-stroke infection: A systematic review
and meta-analysis. BMC neurology, 2011. 11: p. 110.
97. Latorre, M., Krishnareddy, S., and Freedberg, D.E., Microbiome
as mediator: Do systemic infections start in the gut? World J
Gastroenterol, 2015. 21(37): p. 10487-92.
98. Schuijt, T.J., Lankelma, J.M., Scicluna, B.P., et al., The gut micro-
biota plays a protective role in the host defence against pneumo-
coccal pneumonia. Gut, 2016. 65(4): p. 575-83.
99. Dickson, R.P. and Cox, M.J., The premature invocation of a 'gut-
lung axis' may obscure the direct effects of respiratory microbiota
on pneumonia susceptibility. Gut, 2016.
100. Langdon, A., Crook, N., and Dantas, G., The effects of antibiotics
on the microbiome throughout development and alternative ap-
proaches for therapeutic modulation. Genome Med, 2016. 8(1):
p. 39.
101. Jernberg, C., Lofmark, S., Edlund, C., and Jansson, J.K., Long-
term ecological impacts of antibiotic administration on the human
intestinal microbiota. ISME J, 2007. 1(1): p. 56-66.
102. Meisel, A. and Smith, C.J., Prevention of stroke-associated pneu-
monia: where next? Lancet, 2015.
103. Springer, J., Schust, S., Peske, K., et al., Catabolic signaling and
muscle wasting after acute ischemic stroke in mice: indication for
a stroke-specific sarcopenia. Stroke, 2014. 45(12): p. 3675-83.
104. Scherbakov, N., Dirnagl, U., and Doehner, W., Body weight after
stroke: lessons from the obesity paradox. Stroke; a journal of ce-
rebral circulation, 2011. 42(12): p. 3646-50.
105. Turnbaugh, P.J., Backhed, F., Fulton, L., and Gordon, J.I., Diet-
induced obesity is linked tomarked but reversible alterations in the
mouse distal gut microbiome. Cell Host Microbe, 2008. 3(4): p.
213-23.
106. Bindels, L.B., Beck, R., Schakman, O., et al., Restoring specific
lactobacilli levels decreases inflammation and muscle atrophy
markers in an acute leukemia mouse model. PLoS One, 2012.
7(6): p. e37971.
107. Robinson, R.G. and Jorge, R.E., Post-Stroke Depression: A
Review. Am J Psychiatry, 2016. 173(3): p. 221-31.
108. Fetissov, S.O. and Dechelotte, P., The new link between gut-brain
axis and neuropsychiatric disorders. Curr Opin Clin Nutr Metab
Care, 2011. 14(5): p. 477-82.
109. Yarandi, S.S., Peterson, D.A., Treisman, G.J., Moran, T.H., and
Pasricha, P.J., Modulatory Effects of Gut Microbiota on the
Central Nervous System: How Gut Could Play a Role in
Neuropsychiatric Health and Diseases. J Neurogastroenterol
Motil, 2016. 22(2): p. 201-12.
110. Forsythe, P., Sudo, N., Dinan, T., Taylor, V.H., and Bienenstock,
J., Mood and gut feelings. Brain Behav Immun, 2010. 24(1): p. 9-
16.
111. Jiang, H., Ling, Z., Zhang, Y., et al., Altered fecal microbiota
composition in patients with major depressive disorder. Brain
Behav Immun, 2015. 48: p. 186-94.
112. Jia, W., Li, H., Zhao, L., and Nicholson, J.K., Gut microbiota: a
potential new territory for drug targeting. Nat Rev Drug Discov,
2008. 7(2): p. 123-9.
113. Ashraf, R. and Shah, N.P., Immune system stimulation by probi-
otic microorganisms. Crit Rev Food Sci Nutr, 2014. 54(7): p. 938-
56.
114. Besselink, M.G., van Santvoort, H.C., Renooij, W., et al.,
Intestinal barrier dysfunction in a randomized trial of a specific
probiotic composition in acute pancreatitis. Ann Surg, 2009.
250(5): p. 712-9.
115. Gooszen, H.G. and Dutch Pancreatitis Study, G., The
PROPATRIA trial: best practices at the time were followed.
Lancet, 2010. 375(9722): p. 1249-50.
116. Dani, C., Coviello, C.C., Corsini, I.I., Arena, F., Antonelli, A., and
Rossolini, G.M., Lactobacillus Sepsis and Probiotic Therapy in
Newborns: Two New Cases and Literature Review. AJP Rep,
2016. 6(1): p. e25-9.
117. Oggioni, M.R., Pozzi, G., Valensin, P.E., Galieni, P., and Bigazzi,
C., Recurrent septicemia in an immunocompromised patient due
to probiotic strains of Bacillus subtilis. J Clin Microbiol, 1998.
36(1): p. 325-6.
118. Kochan, P., Chmielarczyk, A., Szymaniak, L., et al., Lactobacillus
rhamnosus administration causes sepsis in a cardiosurgical pa-
tient–is the time right to revise probiotic safety guidelines? Clin
Microbiol Infect, 2011. 17(10): p. 1589-92.
119. Eiseman, B., Silen, W., Bascom, G.S., and Kauvar, A.J., Fecal
enema as an adjunct in the treatment of pseudomembranous en-
terocolitis. Surgery, 1958. 44(5): p. 854-9.
120. van Nood, E., Vrieze, A., Nieuwdorp, M., et al., Duodenal infu-
sion of donor feces for recurrent Clostridium difficile. N Engl J
Med, 2013. 368(5): p. 407-15.
121. Vermeire, S., Joossens, M., Verbeke, K., et al., Donor Species
Richness Determines Faecal Microbiota Transplantation Success
in Inflammatory Bowel Disease. J Crohns Colitis, 2016. 10(4): p.
387-94.
122. Petrof, E.O., Gloor, G.B., Vanner, S.J., et al., Stool substitute
transplant therapy for the eradication of Clostridium difficile in-
fection: 'RePOOPulating' the gut. Microbiome, 2013. 1(1): p. 3.
123. Didesch, M.M., Averill, A., and Oh-Park, M., Peripheral
Neuropathy After Fecal Microbiota Transplantation for
Clostridium difficile Infection: A Case Report. PM R, 2016.
124. Gregory, J.C., Buffa, J.A., Org, E., et al., Transmission of athero-
sclerosis susceptibility with gut microbial transplantation. J Biol
Chem, 2015. 290(9): p. 5647-60.
125. Perie-FlomCenter, Bill of Health http://blogs.harvard.
edu/billofhealth/2016/03/01/fda-announces-draftguidance-that-
would-limit-enforcement-discretion-for-fmt. Accessed on 29th of
March 2016.
126. Belizario, J.E. and Napolitano, M., Human microbiomes and their
roles in dysbiosis, common diseases, and novel therapeutic ap-
proaches. Front Microbiol, 2015. 6: p. 1050.
127. Chow, J. and Mazmanian, S.K., Getting the bugs out of the im-
mune system: do bacterial microbiota "fix" intestinal T cell re-
sponses? Cell Host Microbe, 2009. 5(1): p. 8-12.
128. Maslowski, K.M., Vieira, A.T., Ng, A., et al. Regulation of inflam-
matory responses by gut microbiota and chemoattractant receptor
GPR43. Nature, 2009. 461(7268): p. 1282-6.
Therapeutic Manipulations of the Gut Microbiome in CNS Diseases 773
129. Spanogiannopoulos, P., Bess, E.N., Carmody, R.N., and
Turnbaugh, P.J. The microbial pharmacists within us: a
metagenomic view of xenobiotic metabolism. Nat Rev
Microbiol, 2016. 14(5): p. 273-87.
130. Sousa, T., Paterson, R.,Moore, V., Carlsson, A., Abrahamsson, B.,
and Basit, A.W. The gastrointestinal microbiota as a site for the
biotransformation of drugs. Int J Pharm, 2008. 363(1-2): p. 1-25.
131. Haiser, H.J. and Turnbaugh, P.J. Is it time for a metagenomic basis
of therapeutics? Science, 2012. 336(6086): p. 1253-5.
132. Wallace, B.D.,Wang, H., Lane, K.T., et al. Alleviating cancer drug
toxicity by inhibiting a bacterial enzyme. Science, 2010.
330(6005): p. 831-5.
133. Vetizou, M., Pitt, J.M., Daillere, R., et al. Anticancer immunother-
apy by CTLA-4 blockade relies on the gut microbiota. Science,
2015. 350(6264): p. 1079-84.
134. Sivan, A., Corrales, L., Hubert, N., et al. Commensal
Bifidobacterium promotes antitumor immunity and facilitates an-
ti-PD-L1 efficacy. Science, 2015. 350(6264): p. 1084-9.
135. Lemon, K.P., Armitage, G.C., Relman, D.A., and Fischbach,M.A.
Microbiota-targeted therapies: an ecological perspective. Sci
Transl Med, 2012. 4(137): p. 137rv5.
136. Kleiman, S.C., Watson, H.J., Bulik-Sullivan, E.C., et al. The in-
testinal microbiota in acute anorexia nervosa and during
renourishment: relationship to depression, anxiety, and eating dis-
order psychopathology. Psychosom Med, 2015. 77(9): p. 969-
981.
137. Krajmalnik-Brown, R., Lozupone, C., Kang, D.W., and Adams,
J.B. Gut bacteria in children with autism spectrum disorders: chal-
lenges and promise of studying how a complex community influ-
ences a complex disease. Microb Ecol Health Dis 2015. 26: p.
26914.
774 Winek et al.
